Inhibrx Inc (INBX)

NASDAQ
25.88
+1.11(+4.48%)
After Hours
25.88
0.00(0.00%)
- Real-time Data
  • Volume:
    168,901
  • Bid/Ask:
    23.50/27.37
  • Day's Range:
    24.29 - 26.93

INBX Overview

Prev. Close
24.77
Day's Range
24.29-26.93
Revenue
12.91M
Open
25.02
52 wk Range
14.27-50.97
EPS
-2.23
Volume
168,901
Market Cap
978.54M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
146,878
P/E Ratio
-
Beta
-
1-Year Change
-
Shares Outstanding
37,810,751
Next Earnings Date
Sep 01, 2021
What is your sentiment on Inhibrx Inc?
or
Market is currently closed. Voting is open during market hours.

Inhibrx Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyNeutralBuyStrong BuyStrong Buy
Technical IndicatorsStrong SellStrong SellStrong BuyStrong BuyBuy
SummaryNeutralSellStrong BuyStrong BuyStrong Buy

Inhibrx Inc Company Profile

Inhibrx Inc Company Profile

Employees
91

Inhibrx Inc. is a clinical-stage biotechnology company. The Company is focused on developing biologic therapeutics for people with life-threatening conditions. It has a pipeline of novel biologic therapeutic candidates, developed using its single domain antibody (sdAb) platform. Its pipeline includes INBRX-109, INBRX-106, INBRX-105 and INBRX-101. INBRX-109 is a tetravalent death receptor 5 (DR5) agonist being evaluated in patients diagnosed with chondrosarcoma and mesothelioma cancers. INBRX-106 is a hexavalent OX40 agonist being investigated in patients with locally advanced or metastatic solid tumors. INBRX-105 is a precisely engineered tetravalent sdAb based therapeutic candidate, acting both as an antagonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB. INBRX-101 is a precisely engineered recombinant human AAT-Fc fusion protein therapeutic candidate, in development for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.